Michele M. Simkin biedt strategisch zakelijk advies aan cliënten in de biowetenschappen, farmaceutische industrie en medische hulpmiddelen met betrekking tot alle aspecten van intellectueel eigendom, waaronder de verwerving en het beheer van octrooien, licentieovereenkomsten, due diligence met betrekking tot de verwerving of verkoop van intellectueel eigendom, evenals analyses van geldigheid, niet-inbreuk en freedom to operate. Ze is partner in de chemische, biotechnologische en farmaceutische praktijk van het kantoor. Eerder was ze voorzitter van de afdeling Intellectueel Eigendom van het kantoor, waar ze toezicht hield op een team van meer dan 300 IE-professionals, en momenteel is ze lid van het Management Committee van het kantoor.

Michele represents a diverse range of clients, including pharmaceutical/biotechnology companies such as Alkermes Pharmaceuticals, 10x Genomics, Inc., and Celgene Corporation (now part of Bristol Myers Squibb), mid-sized biotechnology companies such as MacroGenics, Inc., EnGeneIC Ltd., and 22nd Century Group, Inc., manufacturing companies such as Stoner, Inc. (maker of Invisible Glass products), universities such as University of Pittsburgh, and start-up ventures in both traditional pharmaceuticals and biotechnology applications, such as Enterin, Inc. and BlueWillow Biologics, Inc.

Michele started her patent career in 1988 as a patent examiner in the biotechnology group of the U.S. Patent and Trademark Office. While an undergraduate, Michele worked in the laboratory of Professor David L. Nelson, culturing and harvesting the protozoan Paramecium, which were used as a model to study signal transductions using biochemical, genetic, molecular genetic, cell biological, and electrophysiological tools.